COVID-19 Spike-host cell receptor GRP78 binding site prediction

doi:10.21203/rs.2.24599/v1

Download PDF

Research Article

COVID-19 Spike-host cell receptor GRP78 binding site prediction

https://doi.org/10.21203/rs.2.24599/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Coronaviruses have been circulating between animals and humans repeatedly. A novel human coronavirus, named COVID-19, has recently emerged in Hubei Province, China. Within the first two months, more than 2200 deaths have been confirmed, and there have been more than 79,000 hospitalized patients, mainly in China. Understanding the virus mode of host cell recognition may help to fight the disease and save lives. The spike protein of coronaviruses is the main driving force for host cell recognition. In this study, the COVID-19 corona viral spike binding site to the cell-surface receptor (Glucose Regulated Protein 78 (GRP78)) is predicted using combined molecular modeling docking and structural bioinformatics. The cyclic peptide Pep42 (CTVALPGGYVRVC) was reported earlier to be the docking platform of GRP78 in cancer cells. The COVID-19 spike protein is modeled using its counterpart, the SARS spike. Sequence and structural alignments show that four regions, in addition to its cyclic nature (the S-S bond), have sequence and physicochemical similarities to the cyclic Pep42. Protein-protein docking was performed to test the four regions of the spike that fit tightly in the GRP78 Substrate Binding Domain β (SBDβ). The docking pose revealed the involvement of the SBDβ of GRP78 and the receptor-binding domain of the coronavirus spike protein in recognition of the host cell receptor. We reveal that the binding is more favorable between regions III (C391-C525) and IV (C480-C488) of the spike protein model and GRP78. Region IV is the main driving force for GRP78 binding with the predicted binding affinity of -9.8 kcal/mol. These nine residues (region IV) of the spike can be used to develop therapeutics specific against COVID-19.

Biophysics

Infectious Diseases

GRP78

BiP

COVID-19 spike

protein-protein docking

structural bioinformatics

Pep42

In late December 2019, it was noticed that several people in Wuhan city of Hubei Province, China, were suffering from SARS-like pneumonia, which the World Health Organization (WHO) would later name COVID-19 ^1,2. According to the WHO surveillance draft, in January 2020, any resident or citizen in transit through Wuhan city 14 days before the onset of the symptoms is suspected to be infected by COVID-19 ^2,3. Additionally, WHO distributed interim guidance for laboratories that carry out the testing for the newly emerged outbreak and infection prevention and control guidance ^4,5. The COVID-19 virus is suspected of having emerged in an unknown animal (perhaps a bat) and to have subsequently been transmitted to humans in the seafood and wild animal market ¹. All over the world, there are surveillance borders to prevent the spread of the new unknown coronavirus, while some countries stopped flights to and from China ⁶. By the first week of the year 2020, 41 cases were confirmed to be COVID-19 positive, leaving one person dead and seven in critical care ⁷. This number is continuously increasing on a daily basis. The number of confirmed cases at the time of writing this manuscript exceeded 67,000, and there were confirmed 1526 deaths, mainly in China. On January 20, 2020, the National Health Commission of China confirmed the human-to-human transmission of the new coronavirus outbreak ⁷. Ten days later, WHO declared COVID-19 as a Public Health Emergency of International Concern (PHEIC). COVID-19 symptoms include fever, malaise, dry cough, shortness of breath, and respiratory distress ¹.

COVID-19 is a member of Betacoronaviruses, like the former human coronaviruses SARS and MERS ^8,9. With this novel human coronavirus, there are now seven different strains of Human coronaviruses (HCoVs), namely, 229E and NL63 strains of HCoVs (Alphacoronaviruses), OC43, HKU1, SARS, MERS, and COVID-19 HCoVs (Betacoronaviruses) ^1,8,10. SARS and MERS HCoV are the widely known strains of coronaviruses, and each has caused about 800 deaths. According to WHO, the mortality rates for SARS and MERS HCoV are 10% and 36%, respectively. ^8,10-13. COVID-19 has a 2% mortality rate, but only in a few months will we know how fast the new virus spreads.

HCoVs are positive-sense, long (30,000 bp) single-stranded RNA viruses. Two groups of proteins characterize HCoVs; structural proteins such as Spike (S) that characterize all coronaviruses, Nucleocapsid (N), Matrix (M), and Envelope (E), in addition to the non-structural proteins, such as proteases (nsp3 and nsp5) and RdRp (nsp12) ^8,14. The Spike protein is a crucial recognition factor for virus attachment and entry to the host cells. It is present on the virion’s outer surface in a homo-trimeric state ^14,15.

The Glucose Regulating Protein 78 (GRP78) or Binding immunoglobulin protein (BiP) is the master chaperone protein of the unfolded protein response (when unfolded or misfolded proteins accumulate) ^16-19. Under reasonable conditions, GRP78 is found in the lumen of the Endoplasmic Reticulum (ER) bound to and inactivating three enzymes responsible for cell death or differentiation. These enzymes are Activating Transcription Factor 6 (ATF6), Protein kinase RNA-like Endoplasmic Reticulum Kinase (PERK), and Inositol-requiring Enzyme 1 (IRE1) ¹⁴. Above a threshold of accumulated unfolded proteins, GRP78 releases ATF6, PERK, and IRE1, leading to their activation. Inhibition of protein synthesis and enhancement of the refolding is the end result of the enzymes’ activation ^14,20. Overexpression of GRP78 is also initiated upon cell stress, which increases the chance for GRP78 to escape ER retention and translocate to the cell membrane. Once translocated to the cell membrane, GRP78 is susceptible to virus recognition by its substrate-binding domain (SBD), and it can mediate the virus entry in the cell ¹⁴. Pep42 is a cyclic peptide that has been reported to bind the GRP78 overexpressed and expressed at the surface of cancer cells ²¹.

In this study, the spike protein of COVID-19 was modeled using solved structures in the protein data bank ²². After model validation, molecular docking was performed to test its binding affinity against GRP78. We hypothesized that GRP78 binds to COVID-19, as it happens in the case of the MERS-CoV coronavirus ²³, and we tried to predict the binding site using the similarity between Pep42 and the COVID-19 Spike protein ¹⁴. Four regions of the spike were predicted to be the binding site to GRP78 based on sequence and structural similarity. The results are promising and suggest the possible recognition of the COVID-19 spike by the cell-surface GRP78 upon cell stress.

All human coronaviruses (HCoV) spike proteins were downloaded from the National Center for Biotechnology Information (NCBI) ²⁴. Multiple Sequence Alignment (MSA) of all of the sequences was performed using the Clustal Omega web server of the European Bioinformatics Institute (EMBL-EBI) ²⁵. ESpript 3 software was used to represent the MSA ²⁶. The pairwise sequence identity between COVID-19 spike protein and each of the other HCoV spike proteins was calculated using the same method.

A model was built for the COVID-19 spike using the SWISS-MODEL web server ²⁷. The SARS HCoV spike (PDB ID: 6ACD, chain C), as the closest spike protein to COVID-19 among all of the human coronaviruses, was used as a template for building the COVID-19 spike. The structural superposition of the SARS spike (6ACD, chain C) and COVID-19 spike model was performed using PyMOL software ²⁸.

Four regions are selected from the COVID-19 spike protein receptor-binding domain (RBD). These regions are cyclic (starting and ending with Cysteine residues connected by a disulfide bond) and were hypothesized to be a possible binding site to GRP78 based on the alignment with the Pep42 cyclic peptide. Pairwise sequence alignment was performed for the Pep42 peptide against the four predicted regions of the COVID-19 spike utilizing the Clustal Omega web server. ProtScale web server of the ExPASy bioinformatic resource portal was used to compare the Pep42 sequence to the four regions of the COVID-19 spike that we hypothesized to be the binding site to GRP78 ²⁹. The Kyte & Doolittle hydrophobicity index was calculated for each residue of the peptides, while the grand average hydrophobicity (GRAVY) was calculated for each region of the spike and Pep42.

Molecular docking was utilized to test the binding affinity of the four regions of the COVID-19 spike against the solved structure of GRP78 Substrate Binding Domain (SBD) β. The only solved structure of wild-type, full-length GRP78 bound to ATP in the open configuration found in the PDB database is 5E84 ^30,31. The coordinates of 5E84 were downloaded and prepared for the docking experiment by removing water ions and the ligand. The solvated docking software, HADDOCK, was used in this study to dock the four regions of the spike model for COVID-19 against the solved structure of GRP78 ³². The easy interface was utilized since no restraints are defined ³³. GRP78 active residues (I426, T428, V429, V432, T434, F451, S452, V457, and I459) were retrieved from the literature ³⁰. The active residues from the COVID-19 spike protein were chosen for each region of the spike to be the hydrophobic residues. In both proteins, the residues surrounding the active residues were selected as passive in HADDOCK.

Active residues are the amino acid residues from the two interacting proteins’ binding sites that take part in direct interaction with the other protein partner while passive residues are the residues that can interact indirectly in HADDOCK ^33-36.

Furthermore, Pep42 is tested against the GRP78 solved structure to compare its binding affinity to that of the four regions of the spike protein. The Pep42 3D structure was generated using the I-Tasser web server ³⁷. Pep42 was treated as cyclic during the docking experiment (a distance restraint is added to HADDOCK) since the cyclic form of Pep42 is the selectivity determinant against GRP78 recognition ^38,39.

After docking, the docking complexes were analyzed by the aid of the Protein-Ligand Interaction Profiler (PLIP) web server of Technical University, Dresden ⁴⁰. Two main types of interactions are established upon docking: H-bonding and hydrophobic interactions. PRODIGY software was used to predict the binding affinity for each region of the spike to GRP78. The average docking scores and the residues that take part in the interactions are discussed.

Sequence and Structural Alignment

Figure 1A shows part of the Multiple Sequence Alignment (MSA) between the seven human coronaviruses (229E, NL63, OC43, HKU1, SARS, MERS, and COVID-19) spike proteins performed by Clustal Omega web server and visualized by ESpript software. The secondary structure for the COVID-19 spike model is displayed at the top of the MSA, and residual surface accessibility is present at the bottom. Alpha helices are shown by helix while arrows show beta-sheets on the top of the MSA. The residues that are surface accessible are in blue, while buried residues are in white at the bottom of the MSA. Identical residues are highlighted in red, while similar residues are highlighted in yellow. The positions of the disulfide bonds are marked by the green numbers below the accessibility rows in the MSA. 13 disulfide bonds are found in the spike protein from which we predict four regions to be the binding site with cell surface GRP78. These four regions of the spike protein, identified with the disulfides numbers 3, 4, 5, and 6 are marked in the MSA with green, blue, magenta, and red dashed lines, respectively. A complete MSA for the spike protein (1,273 residues) is found in supplementary figure S1.

The SARS spike protein sequence is the closest to the COVID-19 spike, with 77.38% identity. In contrast, OC43, MERS, HKU1, 229E, and NL63 share only 32.81%, 32.79%, 31.86%, 30.35%, and 28.28%, respectively, with COVID-19 spike. Figure 1B shows the superposition of the homo-trimeric COVID-19 spike model (cyan cartoon) and SARS spike structure (PDB ID: 6ACD) (green cartoon). Two views are shown with a vertical axis rotation of 180o. The Root Mean Square Deviation (RMSD) between the two structures is only 0.284 Å, while the sequence identity is 77.38%.

Pep42 versus spike regions

Pep42 is reported to specifically target the cell-surface GRP78 in cancer cells ¹⁴. Its selectivity against GRP78 has been reported for its cyclic form but not for the extended form. This may be due to the rigidity of the cyclic structure of the peptide, which causes the stabilization of the hydrophobic patch formed by C1, V3, A4, L5, V10, V12, and C13. These residues become closer to each other by the aid of the disulfide bond, making the cyclic peptide the perfect docking platform for GRP78 SBDβ

We found 13 disulfide bonds in the COVID-19 spike protein model that form 13 different cyclic regions that may resemble the cyclic Pep42. Four of these disulfides are found in the outer surface of the spike receptor-binding domain that faces the outside part of the virion, a region that has been targeted with neutralizing antibodies against the SARS and MERS spikes. These four regions, namely, the region I C336: C361 (26 residues), region II C379: C432 (54 residues), region III C391: C525 (135 residues), and region IV C480: C488 (9 residues), are marked in Figure 1A.

Figure 2A shows the pairwise sequence alignments between each spike region and Pep42. The percentage of pairwise sequence identity is listed on the right side of each alignment. The percent identity for region III is the most significant (46.15%) compared to other regions (15.38%, 23.08%, and 33.33% for the regions I, II, and IV, respectively). As shown in Figure 2A, region IV is part of region III. Moreover, regions II and III share some residues. Again, identical residues are highlighted in red, while the conserved residues are highlighted in yellow. The secondary structure is shown at the top of the alignment and the surface accessibility at the bottom. Region IV has all of its residues exposed at the surface (either blue, meaning surface accessible, or cyan, for partially accessible residues). For other regions, some residues are surface exposed (blue or cyan), while others are buried (in white).

Figure 2B shows the hydrophobicity index (Kyte & Doolittle) for each suggested region and the Pep42. The grand average hydrophobicity index for each region (GRAVY) is listed in front of each peptide. Regions I, II, and III have negative values of GRAVY (-0.24, -0.30, and - 0.28, respectively). In contrast, region IV has a positive value (0.08), which means that it has a slightly more hydrophobic character compared to other regions. Pep42 has a highly hydrophobic character (GRAVY value of 1.1) that enables it to be recognized by the cell-surface GRP78 ^14,38,39.

Figure 3A shows the structure model of the COVID-19 spike protein model (homo- trimeric) in a colored cartoon representation. Region IV of the spike (C480: C488) is not only cyclic but also surface-accessible and protrudes to the outer side of the spike, i.e., facing the target cell. It has a slightly hydrophobic character, hence resembling the Pep42 cyclic peptide, and it seems suitable to be the binding site to the cell-surface GRP78. Figure 3B shows the region III of the spike (black cartoon). As shown in the enlarged panel, region IV is part of region III and it is the most surface-exposed part of the spike receptor-binding domain. The contribution of region IV (C480: C488) in binding region III to GRP78 is high (-9.8 out of -14.0 kcal/mol)

Binding mode of spike-GRP78

GRP78-COVID-19 spike protein docking was performed using the HADDOCK software in four different ways. Each region of the spike (predicted to be the binding site to GRP78) was used as the binding site to GRP78, using its active residues selected to be that have hydrophobic character. The active residues for region I are: C336, F338, V341, F342, A344, R347, F348, S350, A352, I358, and C361. For region II, the active residues are: C379, V382, L387, I390, C391, F392, V395, A397, F400, V401, I402, V407, I410, A411, I418, A419, L425, F429, and C432. For region III, the active residues are: C391, F392, V395, A397, F400, V401, I402, V407, I410, A411, I418, A419, L425, F429, C432, V433, I434, A435, L441, V445, L452, L455, F456, L461, F464, I468, I472, A475, C480, V483, F486, C488, F490, L492, F497, V503, V510, V511, V512, L513, F515, L517, L518, A520, A522, V524, and C52. Finally, for region IV, the active residues are C480, V483, F486, and C488. For GRP78, the active site residues are retrieved from previous work to be I426, T428, V429, V432, T434, F451, S452, V457, and I459.

Figures 4A and 4B show the binding mode for each of the docking trials (the best-formed complexes from each docking experiment) with green cartoon representing GRP78 and yellow cartoon representing the homo-trimeric COVID-19 spike. All the docking trials proved the possibility of fitting the GRP78 SBDβ to the spike with binding affinities (predicted by PRODIGY) ranging from -9.8 up to -14 kcal/mol. In terms of the orientation of the two interacting proteins, regions III and IV are accepted to be the docking platform. In these two trials, the GRP78 and spike can interact in a head-to-head fashion.

Table 1 summarizes the docking trials of the four regions of the COVID-19 spike protein against GRP78. The docking scores are listed, while the interaction pattern is analyzed by PLIP software and listed in the table. As shown from the docking scores, region IV of the spike is the best docking platform to GRP78, with a score of -143.5 ±4.4. This score is lower (better) than other regions by 18.3%, 15.2%, and 65.5% for the region I, region II, and region III, respectively. The PRODIGY binding affinities are also listed in table 1. The PLIP analysis partially explains the binding affinity. Region IV of the spike interacts with the substrate-binding domain β of GRP78 with five H-bonds (through P479, N481, E484, and N487) and four hydrophobic interactions (through T478, E484, and F486). The average H-bond length for the docking trial of region IV is 2.26 ±0.54, while the average hydrophobic contact length is 3.66 ±0.18. These values are less than other docking trials using other regions.

Figure 5A shows the predicted binding mode of the GRP78 (cyan surface) to the spike of the newly emerged coronavirus (green surface) using region IV of the spike (red surface) as the docking platform. The interacting residues of GRP78 and the spike proteins are shown in yellow and red, respectively. The enlarged panel shows in more detail the interacting residues of GRP78 (yellow sticks) and the region IV of the spike (red cartoon) labeled with its one-letter codes. This binding mode is acceptable since the two proteins are interacting, as when the virus is approaching the target cell (respiratory system cells) expressing its cell-surface receptor, GRP78. Figure 5B shows a hypothetical binding model showing the homotrimer spike (red surface) protein of the COVID-19 bound to a respiratory system cell exposing the GRP78 protein (green surface). This scenario could occur in stressed cells when GRP78 is overexpressed and translocated from the Endoplasmic Reticulum (ER) to the cell membrane (M).

The predicted binding site of the Spike protein to GRP7 found in this study is in good agreement with studies that identified the spike receptor-binding domain using antibodies ^23,41. Knowledge of this binding site could open the door for further experimental and simulation studies on the mode of envelope protein recognition by the highly dynamical GRP78 substrate- binding domain.

Spike protein is an essential viral element that helps in the attachment and virus internalization to the host cell. A vast amount of host cell receptors are targets for viruses, including the cell-surface GRP78. Inhibiting the interaction that occurs between the COVID–19 spike protein and the host cell receptor GRP78 would probably decrease the rate of viral infection. Furthermore, a vaccine against the COVID–19 spike protein would likely prevent viral infection. The present in silico perspective suggests the existence of a COVID–19 spike protein- GRP78 binding site, thus paving the route for drug designers to develop suitable inhibitors to prevent the binding and hence the infection. Future work involving the dynamics of GRP78 and the experimental validation is required to suggest potent peptidomimetic inhibitors.

Acknowledgments

We want to acknowledge Mrs. Alaa Ismail for helpful discussions and suggestions. We thank LetPub for its linguistic assistance during the preparation of this manuscript.

Competing Interest

All of the authors declare that there is no competing interest in this work.

Data Availability

The docking structures are available upon request from the corresponding author.

Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases 2020; 91: 264-6.
Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of Unknown Etiology in Wuhan, China: Potential for International Spread Via Commercial Air Travel. Journal of Travel Medicine
Organization WH. Surveillance case definitions for human infection with novel coronavirus ( nCoV): interim guidance v1, January 2020: World Health Organization,
Organization WH. Laboratory testing of human suspected cases of novel coronavirus ( nCoV) infection: interim guidance, 10 January 2020: World Health Organization,
Organization WH. Infection prevention and control during health care when novel coronavirus ( nCoV) infection is suspected: interim guidance, January 2020: World Health Organization,
Parr J. Pneumonia in China: lack of information raises concerns among Hong Kong health workers. British Medical Journal Publishing Group;
Yang L. China confirms human-to-human transmission of coronavirus.
Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. Journal of Medical Virology 2017; 89(6): 1040-7.
Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen K-Y. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clinical microbiology reviews 2015; 28(2): 465-522.
Middle East respiratory syndrome coronavirus (MERS-CoV). 23 june 2016 2016 (accessed 8 October 2016 2016).
Hemida MG, Alnaeem A. Some One Health based control strategies for the Middle East respiratory syndrome coronavirus. One Health 2019; 8:
Báez-Santos YM, Mielech AM, Deng X, Baker S, Mesecar AD. Catalytic Function and Substrate Specificity of the Papain-Like Protease Domain of nsp3 from the Middle East Respiratory Syndrome Coronavirus. Journal of Virology 2014; 88(21): 12511-27.
Organization WH. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus ( MERS-CoV) infection is suspected: interim guidance: World Health Organization,
Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: A cell's response to stress. Life Sciences 2019; 226: 156-63.
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012; 4(6): 1011-33.
Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005; 35(4): 373-81.
Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Current molecular medicine 2006; 6(1): 45-54.
Rao RV, Peel A, Logvinova A, et al. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS letters 2002; 514(2-3): 122-8.
Quinones QJ, Ridder GGd, Pizzo SV. GRP78, a chaperone with diverse roles beyond the endoplasmic reticulum. Histology and histopathology
Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Developmental cell 2002; 3(1): 99-111.
Kim Y, Lillo AM, Steiniger SC, et al. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 2006; 45(31): 9434-44.
Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Mol Biol 2003; 10(12): 980-.
Chu H, Chan C-M, Zhang X, et al. Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. Journal of Biological Chemistry 2018; 293(30): 11709-26.
National Center of Biotechnology Informatics (NCBI) database website http://www.ncbi.nlm.nih.gov/. 2020. http://www.ncbi.nlm.nih.gov/2020).
Notredame C, Higgins DG, Heringa J. T-Coffee: A novel method for fast and accurate multiple sequence alignment. Journal of molecular biology 2000; 302(1): 205-17.
Gouet P, Courcelle E, Stuart DI, M√© toz F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics (Oxford, England) 1999; 15(4): 305-8.
Biasini M, Bienert S, Waterhouse A, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research 2014; 42(W1): W252-W8.
7.6 V. The PyMOL Molecular Graphics System, Version 1.7.6 Schrödinger, LLC.
Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook: Springer; 2005: 571-607.
Yang J, Nune M, Zong Y, Zhou L, Liu Q. Close and Allosteric Opening of the Polypeptide-Binding Site in a Human Hsp70 Chaperone BiP. Structure 2015; 23(12): 2191-203.
Yang J, Zong Y, Su J, et al. Conformation transitions of the polypeptide-binding pocket support an active substrate release from Hsp70s. Nature Communications 2017; 8(1):
van Dijk AD, Bonvin AM. Solvated docking: introducing water into the modelling of biomolecular complexes. Bioinformatics 2006; 22(19): 2340-7.
de Vries SJ, van Dijk M, Bonvin AM. The HADDOCK web server for data-driven biomolecular docking. Nat Protoc 2010; 5(5): 883-97.
de Vries SJ, van Dijk ADJ, Krzeminski M, et al. HADDOCK versus HADDOCK: New features and performance of HADDOCK2.0 on the CAPRI targets. Proteins: Structure, Function, and Bioinformatics 2007; 69(4): 726-33.
van Dijk AD, de Vries SJ, Dominguez C, Chen H, Zhou HX, Bonvin AM. Data-driven docking: HADDOCK's adventures in CAPRI. Proteins 2005; 60(2): 232-8.
Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein− protein docking approach based on biochemical or biophysical information. Journal of the American Chemical Society 2003; 125(7): 1731-7.
Zhang Y. I-TASSER server for protein 3D structure prediction. BMC bioinformatics 2008; 9(1):
Yoneda Y, Steiniger SC, Capkova K, et al. A cell-penetrating peptidic GRP78 ligand for tumor cell- specific prodrug therapy. Bioorg Med Chem Lett 2008; 18(5): 1632-6.
Kim Y, Lillo AM, Steiniger SC, et al. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 2006; 45(31): 9434-44.
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein– ligand interaction profiler. Nucleic acids research 2015; 43(W1): W443-W7.
Pujhari S, Macias VM, Nissly RH, Nomura M, Kuchipudi SV, Rasgon JL. Heat shock protein 70 (Hsp70) is involved in the Zika virus cellular infection process. bioRxiv 2017:

Table 1 is not available with this version of the manuscript.

FigureS1.pdf

Download PDF

Version 1

posted

You are reading this latest preprint version

COVID-19 Spike-host cell receptor GRP78 binding site prediction

Status:

Version 1

Abstract

Figures

Introduction

Materials And Methods

Results And Discussion

Sequence and Structural Alignment

Pep42 versus spike regions

Binding mode of spike-GRP78

Conclusion

Declarations

References

Table

Supplementary Files

Status:

Version 1